The Motley Fool Previous Page

J&J's Been Busy

Brian Orelli
July 7, 2011

When it comes to virus inhibition, Johnson & Johnson (NYSE: JNJ  ) has been getting around. Last week, the health-care giant signed a partnership with Gilead Sciences (Nasdaq: GILD  ) to combine their HIV drugs. And yesterday, Johnson & Johnson announced it was hooking up with a different partner, Pharmasset (Nasdaq: VRUS  ) , to cre